Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DINA IBRAHIM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1780625376
CMS profile
353736
Location
FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,898.93

164 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,711.95 162
Education $186.98 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $453.06 19
PFIZER INC. $308.03 12
Daiichi Sankyo Inc. $261.91 16
Exelixis Inc. $218.65 9
Janssen Biotech, Inc. $174.07 5
AstraZeneca Pharmaceuticals LP $172.85 7
Astellas Pharma US Inc $155.41 8
GlaxoSmithKline, LLC. $137.81 9
Alexion Pharmaceuticals, Inc. $131.35 4
SOBI, INC $119.39 5
Genentech USA, Inc. $110.56 5
ABBVIE INC. $109.35 4
Eisai Inc. $101.03 4
Takeda Pharmaceuticals U.S.A., Inc. $93.09 4
Stemline Therapeutics Inc. $88.80 3
SEAGEN INC. $86.99 1
Agios Pharmaceuticals, Inc. $82.13 3
Caris MPI, Inc. $80.85 3
Boehringer Ingelheim Pharmaceuticals, Inc. $79.01 4
ARRAY BIOPHARMA INC $74.63 3
SpringWorks Therapeutics, Inc. $71.09 3
Lilly USA, LLC $64.23 3
Celgene Corporation $62.64 3
Merck Sharp & Dohme LLC $58.30 2
PUMA BIOTECHNOLOGY, INC. $54.05 2
GENZYME CORPORATION $50.80 1
Tactile Systems Technology Inc $49.15 1
Regeneron Healthcare Solutions, Inc. $46.93 2
TerSera Therapeutics LLC $45.61 2
Ipsen Biopharmaceuticals, Inc $43.49 2
Syndax Pharmaceuticals, Inc. $31.02 1
Iovance Biotherapeutics, Inc. $27.06 1
Bayer Healthcare Pharmaceuticals Inc. $25.60 1
Incyte Corporation $23.44 1
Geron Corporation $23.22 1
PharmaEssentia USA Corporation $23.19 1
SHIELD THERAPEUTICS INC $22.73 1
RECORDATI_RARE_DISEASES_INC. $19.18 1
Gilead Sciences, Inc. $18.57 1
ADC THERAPEUTICS AMERICA, INC. $18.40 1
Amneal Pharmaceuticals LLC $17.33 1
Tempus AI, Inc $16.47 1
ACCORD HEALTHCARE, INC. $16.13 1
Aveo Pharmaceuticals, Inc. $15.91 1
Azurity Pharmaceuticals, Inc. $15.42 1

Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DINA IBRAHIM

NPI 1780625376 · CMS profile ID 353736

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780625376?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DINA IBRAHIM, NPI 1780625376, CMS profile ID 353736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780625376?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DINA IBRAHIM, NPI 1780625376, CMS profile ID 353736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780625376?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DINA IBRAHIM, NPI 1780625376, CMS profile ID 353736, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780625376?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

164 matching records · $3,898.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 164 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 164.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $18.5104/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174612339 CMS
Iovance Biotherapeutics, Inc. $27.0604/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251398497 CMS
Lilly USA, LLC $14.7404/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186637831 CMS
Daiichi Sankyo Inc. $27.5704/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197098393 CMS
SOBI, INC $22.0004/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240274047 CMS
PFIZER INC. $12.4904/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229366578 CMS
Geron Corporation $23.2204/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238889426 CMS
Daiichi Sankyo Inc. $27.9404/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197037751 CMS
Daiichi Sankyo Inc. $3.1904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197057223 CMS
Daiichi Sankyo Inc. $28.7504/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197058201 CMS
Exelixis Inc. $22.7404/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218793637 CMS
Celgene Corporation $17.7404/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184881007 CMS
Stemline Therapeutics Inc. $34.3604/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244091940 CMS
Novartis Pharmaceuticals Corporation $32.3303/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200321730 CMS
Astellas Pharma US Inc $31.8003/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238764302 CMS
Astellas Pharma US Inc $2.0003/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238763108 CMS
ABBVIE INC. $22.5603/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202090011 CMS
ARRAY BIOPHARMA INC $19.7003/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229234274 CMS
Exelixis Inc. $16.1703/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218793633 CMS
GlaxoSmithKline, LLC. $17.0103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190510617 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.9603/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223840267 CMS
Novartis Pharmaceuticals Corporation $16.5803/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200321750 CMS
Novartis Pharmaceuticals Corporation $32.9003/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200321722 CMS
Celgene Corporation $22.0503/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184880975 CMS
GlaxoSmithKline, LLC. $12.1403/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191680098 CMS
Regeneron Healthcare Solutions, Inc. $15.3503/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212947830 CMS
Incyte Corporation $23.4403/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226045368 CMS
SpringWorks Therapeutics, Inc. $25.4603/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232163537 CMS
SOBI, INC $20.0003/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240274038 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.7402/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223038535 CMS
Eisai Inc. $22.7602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244476710 CMS
ABBVIE INC. $33.3502/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202090009 CMS
Azurity Pharmaceuticals, Inc. $15.4202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242672752 CMS
GENZYME CORPORATION $50.8002/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233319005 CMS
Novartis Pharmaceuticals Corporation $12.2002/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200321728 CMS
Lilly USA, LLC $26.9302/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186581200 CMS
PFIZER INC. $9.2202/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229241990 CMS
Merck Sharp & Dohme LLC $30.5502/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238057055 CMS
ABBVIE INC. $25.6802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202090007 CMS
Daiichi Sankyo Inc. $13.9802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197047501 CMS
SOBI, INC $34.3802/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240274042 CMS
GlaxoSmithKline, LLC. $0.9102/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190415547 CMS
GlaxoSmithKline, LLC. $24.1102/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190601731 CMS
Gilead Sciences, Inc. $18.5702/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234543483 CMS
Celgene Corporation $22.8502/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184880965 CMS
Exelixis Inc. $22.2102/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218793631 CMS
ACCORD HEALTHCARE, INC. $16.1302/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248746703 CMS
Agios Pharmaceuticals, Inc. $18.5302/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253258348 CMS
PFIZER INC. $21.3602/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229315691 CMS
AstraZeneca Pharmaceuticals LP $26.4101/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206395356 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,571.15 123
PY2020 $226.13 11
PY2021 $340.25 6
PY2022 $551.03 13
PY2023 $806.14 30
PY2024 $3,456.24 155
PY2025 $3,898.93 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,765.78 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,729.13 12/31/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228816966
Principal investigator 1 PFIZER INC. $9,185.00 12/27/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228816668
Principal investigator 1 PFIZER INC. $2,018.80 12/13/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228816893
Principal investigator 1 PFIZER INC. $57,300.60 12/10/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716683
Principal investigator 1 PFIZER INC. $7.50 12/10/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716685
Principal investigator 1 PFIZER INC. $3,651.73 11/26/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228818686
Principal investigator 1 PFIZER INC. $22.50 11/20/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715335
Principal investigator 1 PFIZER INC. $5,153.23 10/31/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228824976
Principal investigator 1 PFIZER INC. $4,028.50 10/09/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228824930
Principal investigator 1 PFIZER INC. $15.00 09/24/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716513
Principal investigator 1 PFIZER INC. $25,000.00 09/24/2025 Non-covered Recipient Entity
ClinRe Inc
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228837506
Principal investigator 1 PFIZER INC. $22,920.15 09/18/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715337
Principal investigator 1 PFIZER INC. $3,154.20 09/08/2025 Non-covered Recipient Entity
ClinR 001022 Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228717461
Principal investigator 1 PFIZER INC. $7.50 08/28/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228715507
Principal investigator 1 PFIZER INC. $2,184.00 08/07/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228838911
Principal investigator 1 PFIZER INC. $387.94 07/22/2025 Non-covered Recipient Entity
Premier Cancer Care and Infusion Center
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228844612